

**ANDROGENS/ANABOLIC STEROID
PRIOR AUTHORIZATION REQUEST
PRESCRIBER FAX FORM**



**BlueCross BlueShield
of Oklahoma**

Only the prescriber may complete this form. This form is for prospective, concurrent, and retrospective reviews.

Incomplete forms will be returned for additional information. The following documentation is required for preauthorization consideration. For formulary information and to download additional forms, please visit www.bcbsok.com.

What is the priority level of this request?

- Standard review
- Expedited/Urgent review – prescriber certifies that waiting for a standard review could seriously harm the patient’s life, health or ability to regain maximum function

Today’s Date: _____

PATIENT AND INSURANCE INFORMATION

Date of Service (if differs from Today’s Date): _____

Patient Name (First):	Last:	M:	DOB (mm/dd/yyyy):
Patient Address:		City, State, Zip:	
Member ID Number:		Group Number:	
		Patient Telephone:	

PRESCRIBER/CLINIC INFORMATION

Prescriber Name:	Prescriber NPI#:	Specialty:	Contact Name:
Clinic Name:		Clinic Address:	
City, State, Zip:		Phone #:	Secure Fax #:

PLEASE ATTACH ANY ADDITIONAL INFORMATION THAT SHOULD BE CONSIDERED WITH THIS REQUEST

Patient’s Diagnosis - ICD code plus description:
Medication Requested: _____ Strength: _____
Dosing Schedule: _____ Quantity per Month: _____
<p>***Please note, a copy of lab results with reference range is required. Testosterone levels (free or total) must be confirmed with TWO early morning tests (between 7am and 11am) measured on two separate days. ***</p> <p><u>Total Testosterone level(s) (please provide two pretreatment OR two current levels from within the last 12 months):</u></p> <p>Pretreatment _____ ng/dL Reference range _____ Date: _____ Time drawn: _____ am / pm</p> <p>Pretreatment _____ ng/dL Reference range _____ Date: _____ Time drawn: _____ am / pm</p> <p>Current _____ ng/dL Reference range _____ Date: _____ Time drawn: _____ am / pm</p> <p>Current _____ ng/dL Reference range _____ Date: _____ Time drawn: _____ am / pm</p> <p><u>OR</u></p> <p><u>Free Testosterone level(s) (please provide two pretreatment OR two current levels from within the last 12 months):</u></p> <p>Pretreatment _____ ng/dL Reference range _____ Date: _____ Time drawn: _____ am / pm</p> <p>Pretreatment _____ ng/dL Reference range _____ Date: _____ Time drawn: _____ am / pm</p> <p>Current _____ ng/dL Reference range _____ Date: _____ Time drawn: _____ am / pm</p> <p>Current _____ ng/dL Reference range _____ Date: _____ Time drawn: _____ am / pm</p>
<p>1. Is checking for testosterone levels medically inappropriate for the patient’s gender? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>If yes, please provide explanation: _____</p> <p>_____</p>
<p>Please continue on page 2.</p>

Patient Name (First):	Last:	M:	DOB (mm/dd/yyyy):
-----------------------	-------	----	-------------------

For All Requests:

2. Is the patient currently receiving testosterone replacement therapy? Yes No
If yes, when was treatment started: _____
3. Please select the patient's gender: Male Female
4. Please list all reasons for selecting the requested **medication, quantity and dosing schedule** over alternatives (e.g. contraindications, allergies or history of adverse drug reactions to alternatives, lower dose tried). _____
5. Please list all other medications the patient will take concomitantly with the requested medication. _____
6. Please list all medications the patient has **previously tried and failed for treatment of this diagnosis** (Please specify if brand name, generic, extended-release products or OTC products):
 _____ Date(s): _____ Date(s): _____
 _____ Date(s): _____ Date(s): _____
 _____ Date(s): _____ Date(s): _____
7. Has the patient had significant weight loss following surgery, infection, or trauma? Yes No
8. Does the patient have severe liver disease (Child Pugh Grade III-IV or refractory)? Yes No
9. Does the patient have severe renal disease (Stage 4-5)? Yes No
10. Does the patient have carcinoma of the breast? Yes No
11. Does the patient have known or suspected carcinoma of the prostate? Yes No
12. Does the patient have hypercalcemia? Yes No
13. Is the patient breastfeeding, pregnant or may become pregnant? Yes No
14. Does the patient have cardiac disease? Yes No
15. Does the patient have porphyria? Yes No

For Hypogonadism Diagnosis:

*****Please note, medical records including chart notes must be submitted as documentation to support signs/symptoms of hypogonadism.*****

16. Prior to testosterone replacement therapy, did the patient show signs/symptoms of hypogonadism? Yes No

For Anemia Diagnosis:

17. Please provide patient's hematocrit (Hct) value: _____ %
18. Is the patient's anemia caused by or associated with chronic renal failure? Yes No
19. Is the patient's anemia caused by deficient red cell production, including acquired aplastic anemia, congenital aplastic anemia, myelofibrosis and the hypoplastic anemias due to the administration of myelotoxic drugs? Yes No
20. **If no to both questions 18 and 19**, please provide the cause(s) of the patient's anemia: _____
21. Has the patient previously used an erythropoiesis-stimulating agent? Yes No
If no, please provide explanation why: _____

For AIDS/HIV-associated Wasting Syndrome Diagnosis:

22. Please provide the patient's BMI: _____ kg/m²
23. Has the patient had unexplained involuntary weight loss with obvious wasting? Yes No
If yes, please provide the percent weight loss from baseline body weight: _____ %
24. Have all other causes of weight loss been ruled out? Yes No

For Turner Syndrome Diagnosis:

25. Is the patient a child or adolescent? Yes No
26. Will the patient continue to be concurrently treated with growth hormone? Yes No

Please fax or mail this form to:

Blue Cross and Blue Shield of Oklahoma
 c/o Prime Therapeutics LLC, Clinical Review Department
 1305 Corporate Center Drive
 Eagan, Minnesota 55121

TOLL FREE

Fax: 877.243.6930 Phone: 800.991.5643

CONFIDENTIALITY NOTICE: This communication is intended only for the use of the individual entity to which it is addressed, and may contain information that is privileged or confidential. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify the sender immediately by telephone at 800.858.0723, and return the original message to Blue Cross and Blue Shield of Oklahoma c/o Prime Therapeutics via U.S. Mail. Thank you for your cooperation.